Compare Msci Inc (MSCI) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Repligen Corporation Common Stock — how do they compare? Msci Inc trades at $562.23 (market cap $41.29B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Msci Inc is far larger — about 3.7× Repligen Corporation Common Stock's market cap, and Msci Inc pays a 1.44% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 83 Days and Repligen Corporation Common Stock for 0 Days on average.
| MSCI | RGEN | |
|---|---|---|
Market Cap | $41.29B | $11.14B |
Volume | 468,436 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $643.83 | $194.57 |
52-Week Low | $511.84 | $102.87 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $47.46B | $11.02B |
Dividend Yield | 1.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $560.52, down 1.32% today, with strong profitability (40.73% net margin) and consistent revenue growth from $2.2B in 2022 to $3.1B in 2025. Recent Q2 2026 earnings missed expectations at $4.94 EPS, but Q1 and Q4 2025 beat. Technicals show a bullish moving average signal with RSI at 59.48 neutral, while analyst consensus is strongly bullish with a $701.71 price target. The company maintains robust cash flow from operations of $1.6B in 2025.
Outlook remains positive driven by recurring revenue streams and market position, though high valuation (P/E 31.06) and debt levels ($4.51B long-term) pose risks. The upcoming Q3 2026 earnings on October 20, 2026, is a key catalyst. Investors should weigh strong fundamentals against premium pricing and macroeconomic sensitivity.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
